Ocular side effects of biological agents in oncology: What should the clinician be aware of?

26Citations
Citations of this article
41Readers
Mendeley users who have this article in their library.

Abstract

During the last 20 years, biologicals have become increasingly relevant in oncologic therapy. Depending on the medication used, there are different profiles of ocular side effects. Although these can be present in up to 70% of patients, they are generally underreported in the literature. Therefore, the pathophysiological details of their development are often poorly understood. Herein we attempt to identify groups of biologicals to which a specific side effect profile can be assigned. We also tried to capture all relevant side effects and therefore conducted several database investigation including Medline, Cochrane library, and the drugs section of the US Food and Drug Administration (FDA), using the following search strings: "name of biological agent (both generic and commercial names)" AND "eye" OR "ocular". If we found a side effect that has been associated with a drug, we researched Medline using the following search string: "name of biological agent" (both generic and commercial names) AND "term for the specific side effect". Due to the wealth of material we report only the drugs that are approved by the FDA. © 2014 Hager and Seitz.

References Powered by Scopus

Activity and safety of crizotinib in patients with ALK-positive non-small-cell lung cancer: Updated results from a phase 1 study

1133Citations
N/AReaders
Get full text

Effect of crizotinib on overall survival in patients with advanced non-small-cell lung cancer harbouring ALK gene rearrangement: A retrospective analysis

823Citations
N/AReaders
Get full text

Multicenter phase II study of erlotinib, an oral epidermal growth factor receptor tyrosine kinase inhibitor, in patients with recurrent or metastatic squamous cell cancer of the head and neck

776Citations
N/AReaders
Get full text

Cited by Powered by Scopus

Supportive care for patients undergoing immunotherapy

54Citations
N/AReaders
Get full text

Neuro-ophthalmic side effects of molecularly targeted cancer drugs

37Citations
N/AReaders
Get full text

New-onset uveitis during CTLA-4 blockade therapy with ipilimumab in metastatic melanoma patient

37Citations
N/AReaders
Get full text

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Cite

CITATION STYLE

APA

Hager, T., & Seitz, B. (2013). Ocular side effects of biological agents in oncology: What should the clinician be aware of? OncoTargets and Therapy, 7, 69–77. https://doi.org/10.2147/OTT.S54606

Readers' Seniority

Tooltip

PhD / Post grad / Masters / Doc 12

52%

Professor / Associate Prof. 6

26%

Researcher 4

17%

Lecturer / Post doc 1

4%

Readers' Discipline

Tooltip

Medicine and Dentistry 19

79%

Agricultural and Biological Sciences 3

13%

Pharmacology, Toxicology and Pharmaceut... 1

4%

Computer Science 1

4%

Save time finding and organizing research with Mendeley

Sign up for free